Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00060086
Status:
COMPLETED
Last Update Posted:
2021-06-04
First Post:
2003-05-06
Brief Title:
Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen PSA levels and may be effective in delaying or preventing recurrent prostate cancer
PURPOSE This phase II trial is studying how well pomegranate juice works in decreasing or slowing the rise of PSA levels in patients who have undergone radiation therapy or surgery for prostate cancer
PURPOSE This phase II trial is studying how well pomegranate juice works in decreasing or slowing the rise of PSA levels in patients who have undergone radiation therapy or surgery for prostate cancer
Detailed Description:
OBJECTIVES
Determine whether pomegranate juice can decrease or slow rising prostate-specific antigen PSA levels in patients who have undergone radical prostatectomy or radiotherapy for adenocarcinoma of the prostate
OUTLINE Patients receive oral pomegranate juice once daily Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 29-40 patients will be accrued for this study
Determine whether pomegranate juice can decrease or slow rising prostate-specific antigen PSA levels in patients who have undergone radical prostatectomy or radiotherapy for adenocarcinoma of the prostate
OUTLINE Patients receive oral pomegranate juice once daily Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 29-40 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000299439 | OTHER | UCLA IRB | None |
| UCLA-0210049 | None | None | None |